Data di Pubblicazione:
2015
Abstract:
Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Simvastatin; Triglycerides
Elenco autori:
Cannon, Cp; Blazing, Ma; Giugliano, Rp; Mccagg, A; White, Ja; Theroux, P; Darius, H; Lewis, Bs; Ophuis, To; Jukema, Jw; De Ferrari, Gm; Ruzyllo, W; De Lucca, P; Im, K; Bohula, Ea; Reist, C; Wiviott, Sd; Tershakovec, Am; Musliner, Ta; Braunwald, E; Califf, Rm; for the IMPROVE-IT, Investigators; Cianflone, D
Link alla scheda completa:
Pubblicato in: